(19)
(11) EP 2 482 816 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
14.12.2016 Bulletin 2016/50

(45) Mention of the grant of the patent:
05.10.2016 Bulletin 2016/40

(21) Application number: 10768823.6

(22) Date of filing: 28.09.2010
(51) International Patent Classification (IPC): 
A61K 9/06(2006.01)
A61P 17/12(2006.01)
 A61K 31/485(2006.01)
A61P 31/20(2006.01)
(86) International application number:
PCT/TR2010/000194
(87) International publication number:
WO 2011/040894 (07.04.2011 Gazette 2011/14)

(54)

TOPICAL COMPOSITIONS OF NALTREXONE FOR TREATING SKIN CONDITIONS

TOPISCHE NALTREXON-ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HAUTERKRANKUNGEN

COMPOSITIONS TOPIQUES À BASE DE NALTREXONE POUR TRAITER DES TROUBLES CUTANÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 01.10.2009 TR 200907463

(43) Date of publication of application:
08.08.2012 Bulletin 2012/32

(73) Proprietor: Imuneks Farma Ilaç Sanayi Ve Ticaret A.S.
34349 Istanbul (TR)

(72) Inventors:
  • PISAK, Ibrahim Mustafa Iskender
    Gayrettepe Istanbul 34349 (TR)
  • SELAMOGLU , Mehmet Levent
    Gayrettepe Istanbul 34349 (TR)
  • BINGÖL, Semra
    Gayrettepe Istanbul 34349 (TR)

(74) Representative: Kodron, Felix 
Rechtsanwalt Postfach 2649
55016 Mainz
55016 Mainz (DE)


(56) References cited: : 
US-A1- 2007 265 293
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).